DUBLIN, June 03, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/s7lxqn/2015_strategies) has announced the addition of the "2015 Strategies in the US Therapeutic Drug Monitoring (TDM) Market" report to their offering.
This new 249-page report provides a comprehensive analysis of the US therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.
The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid and Vancomycin.
During the next five years, the TDM market will undergo significant transformation.These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.
"2015 Strategies for the US Therapeutic Drug Monitoring (TDM) Market" is a unique market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses.The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors.
For more information visit http://www.researchandmarkets.com/research/s7lxqn/2015_strategies